Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347892 | 1.00 | LMNA (0.61) | LMNACA12CA1CA9CA2 | |
| SCHEMBL12002589 | 1.00 | LMNA (0.61) | LMNACA12CA1CA9CA2 | |
| SCHEMBL12656550 | 0.78 | LMNA (0.59) | LMNACA12CA1CA9CA2 | |
| SCHEMBL13219298 | 0.78 | LMNA (0.59) | LMNACA12CA1CA9CA2 | |
| Moroxydine SCHEMBL19038555 | 0.76 | LMNA (1.00) | LMNACA12CA1CA9CA2 | |
| Moroxydine SCHEMBL2945594 | 0.76 | LMNA (1.00) | LMNACA12CA1CA9CA2 | |
| SCHEMBL15415485 | 0.76 | HRH3 (0.44) | LMNA | |
| SCHEMBL15415482 | 0.76 | HRH3 (0.44) | LMNA | |
| SCHEMBL30047953 | 0.76 | — | — | |
| SCHEMBL4586887 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4448500-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-111527084-B | Isofuranone compounds useful as HPK1 inhibitors | 百时美施贵宝公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023114822-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3707138-B1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3924329-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11166959-B2 | Isofuranone compounds useful as HPK1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| EP-3707138-A1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-16 | — | — | EP | disclosed |
| CN-1756547-A | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA INC | 2006-04-05 | — | — | CN | disclosed |
| EP-1581213-A1 | 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005030144-A2 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040209886-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| WO-2004058253-A1 | 3,5-DISUBSTITUTED-[1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209886-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | PCNA, DPYD, MALT1 | LMNA 1395/4885CA12 3408/4885CA1 4387/4885 |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | LMNA 4372/4885CA12 4434/4885CA1 3961/4885 |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP3, CASP2 | LMNA 754/4885CA12 4524/4885CA1 1863/4885 |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | LMNA 4372/4885CA12 4434/4885CA1 3961/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | LMNA 85/4885CA12 3323/4885CA1 3665/4885 |
| US-11166959-B2 | Isofuranone compounds useful as HPK1 inhibitors | IP6K1, SIK1, HIPK1 | LMNA 3250/4885CA12 4794/4885CA1 4025/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | LMNA 129/4885CA12 2752/4885CA1 2285/4885 |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP2, RXFP3 | LMNA 4042/4885CA12 4284/4885CA1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.